Gsk (GSK) Liabilities from Discontinued Operations (2022 - 2025)
Gsk (GSK) posted quarterly Liabilities from Discontinued Operations of 184893101.59 for Q4 2025, up 99.18% quarter-over-quarter from 22478758539.5 in Q2 2022.
Gsk (GSK) Liabilities from Discontinued Operations (2022 - 2025) Analysis & Trends
Gsk's Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 184893101.59 for Q4 2025.
- In Q4 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 184893101.59; the TTM figure through Dec 2025 stood at 184893101.59 (changed N/A YoY), while the FY2025 annual figure was 183272936.69, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q4 2025 stood at 184893101.59, up from 22478758539.5 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 184893101.59 in Q4 2025, with the low at 22478758539.5 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -184.89 Mn |
| Dec 31, 2025 | -184.89 Mn |
| Jun 30, 2022 | -22.48 Bn |
| Jun 30, 2022 | -22.48 Bn |